bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 226,200 shares, a decline of 16.7% from the October 31st total of 271,400 shares. Based on an average daily trading volume, of 123,400 shares, the days-to-cover ratio is currently 1.8 days. Approximately 2.4% of the shares of the company are short sold.
bioAffinity Technologies Stock Performance
Shares of NASDAQ:BIAF traded down $0.11 during trading on Monday, hitting $1.11. 42,945 shares of the stock traded hands, compared to its average volume of 137,609. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a 52-week low of $1.03 and a 52-week high of $3.62. The company has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $1.89. The company has a market cap of $17.22 million, a price-to-earnings ratio of -1.48 and a beta of 3.10.
Institutional Investors Weigh In On bioAffinity Technologies
An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is owned by institutional investors.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Read More
- Five stocks we like better than bioAffinity Technologies
- Stock Market Sectors: What Are They and How Many Are There?
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- Ride Out The Recession With These Dividend Kings
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
- What is the NASDAQ Stock Exchange?
- 4 AI-Powered Fintechs Revolutionizing the Future of Finance
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.